Product Description
GT-101 is an injeciton for the treatment of metastatic or recurrent solid tumors. (Sourced from: https://ichgcp.net/clinical-trials-registry/NCT05430373)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cervical Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GT101-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-08-31 |
4% |
2023-10-07 |
Primary Completion Date|Primary Endpoints|Treatments |
| GRIT-CD-FA-013 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-07-01 |
4% |
2025-02-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| CTR20221188 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| GT-CD-CHN-101-02 | P2 |
Recruiting |
Cervical Cancer |
2027-01-31 |
2% |
2025-02-08 |
Patient Enrollment|Primary Endpoints|Treatments |
| CTR20242671 | P2 |
Recruiting |
Cervical Cancer |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
| CTR20234011 | P2 |
Recruiting |
Cervical Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/29/2025 |
News Article |
Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting |
|
05/12/2025 |
News Article |
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting |
|
05/31/2024 |
News Article |
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2 |
|
03/01/2024 |
PubMed |
In vitro Antibacterial Activity of Ethanolic Tanao Si Kan Dang RD1 (Cannabis sativa L.) Extracts Against Human Antibiotic-Resistant Bacteria. |
|
09/08/2023 |
News Article |
Grit Biotechnology Announces Closing of $60 Million Series B Financing |
|
07/28/2020 |
PubMed |
Classification of Pigeonpea (Cajanus cajan (L.) Millsp.) Genotypes for Zinc Efficiency. |